Nutriband Inc. (9WV.F)

3,1600 -0,1600 (-4,82%) Ab 09:24AM CEST. Markt geöffnet.

Nutriband Inc.

121 South Orange Avenue
Suite 1500
Orlando, FL 32801
United States
407 377 6695
https://nutriband.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Serguei Melnik	Founder, President, Company Secretary & Executive Chairman of the Board	185,68k	N/A	1974
Mr. Gareth Sheridan	Founder, CEO & Director	185,68k	N/A	1990
Mr. Gerald Goodman	CFO & Chief Accounting Officer	148,55k	N/A	1948
Dr. Alan Smith Ph.D.	COO & President of 4P Therapeutics	166,19k	N/A	1966
Dr. Jeffrey Patrick Pharm.D.	Chief Scientific Officer	N/A	N/A	1970
Mr. Michael Myer	President of Pocono Pharmaceutical	37,69k	N/A	1985
Mr. Tyler Overk	Head of Active Intelligence	N/A	N/A	1984

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Corporate Governance

Nutriband Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.